COMPOSITION COMPRISING RECOMBINANT GpIba RECEPTOR PROTEIN
AssigneeGrifols Diagnostic Solutions Inc.
InventorsElizabeth Booth, Virginia Montanini, John A. Hall, Jody Berry
Life of this patent
Estimating the term…
Abstract
Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ibα that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.
Claims34
A recombinant polypeptide that specifically binds human von Willebrand Factor, comprising a modified extracellular domain of platelet glycoprotein Ibα, wherein:
- the recombinant polypeptide lacks a transmembrane domain;
- and
- the modified extracellular domain comprises at least one mutation selected from G233T, D235V, and K237V, relative to SEQ ID NO:
- 19.
A recombinant polypeptide that specifically binds human von Willebrand Factor, comprising a modified extracellular domain of platelet glycoprotein Ibα, wherein:
- the modified extracellular domain comprises mutations C65A, G233V and M239V, relative to SEQ ID NO:
- 19.
A recombinant polypeptide that specifically binds human von Willebrand Factor, comprising a modified extracellular domain of platelet glycoprotein Ibα, wherein:
- the modified extracellular domain comprises:
- the A238V mutation;
- or
- the Δ(229-240) mutation, relative to SEQ ID NO:
- 19;
- and
- the recombinant polypeptide has a lower binding affinity for von Willebrand Factor of a human blood or a human blood plasma sample than a control polypeptide that does not comprise the A238V mutation or the Δ(229-240) mutation but that is otherwise identical to the recombinant polypeptide.
Dependencies are inferred from the claim text.